ziprasidone has been researched along with Dyslipidemia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Banks, CD; Deeter, J; Langley, P; Rollins, MR | 1 |
| Bahk, WM; Kim, MD; Kwon, YJ; Lee, HB; Lee, JG; Woo, YS; Yoon, BH | 1 |
| Bobo, WV; Chen, Y; Jayathilake, K; Meltzer, HY; Tang, T; Watts, K | 1 |
| Wooten, J | 1 |
| Perlis, RH | 1 |
| D'Agostino, RB; Eng, SM; Faich, GA; Kane, JM; Reynolds, RF; Ruskin, JN; Strom, BL | 1 |
3 review(s) available for ziprasidone and Dyslipidemia
| Article | Year |
|---|---|
The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Drug Substitution; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Lithium; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Thiazoles; Treatment Outcome; Valproic Acid; Young Adult | 2013 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome; Weight Gain | 2007 |
2 trial(s) available for ziprasidone and Dyslipidemia
| Article | Year |
|---|---|
Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Atherosclerosis; Bipolar Disorder; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Drug Monitoring; Dyslipidemias; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; North America; Patient Dropouts; Piperazines; Psychotic Disorders; Quinolones; Risk Factors; Schizophrenia; Severity of Illness Index; Thiazoles; Weight Loss | 2012 |
The Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC): design and baseline subject characteristics.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hypertension; Long QT Syndrome; Male; Observation; Piperazines; Prevalence; Research Design; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires; Thiazoles; Triglycerides | 2008 |
1 other study(ies) available for ziprasidone and Dyslipidemia
| Article | Year |
|---|---|
New onset metabolic derangement in a pediatric patient receiving therapeutic plasma exchange for anti-NMDA receptor encephalitis.
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antipsychotic Agents; Child; Dyslipidemias; Female; Humans; Piperazines; Plasma Exchange; Plasmapheresis; Receptors, N-Methyl-D-Aspartate; Thiazoles | 2020 |